Low-dose amicizomab will also be effective in hemophilia A, the treatment will be cheaper: study

New -Delhi, June 24 (IANS). A study by the Indian Council of Medical Research found that a low dose of medicine -amiciazumab in the treatment of hemophilia A (genetic bleeding disorder) can be just as effective as standard doses. This drug prevents or reduces bleeding by mimicking blood -rejected coagulation factor VIII. According to official government data, 27,000 hemophilia patients are registered in India and estimated that 1,40,000 people can be affected. The ICMR study revealed that low -dose Ecizimab could be an alternative to affordable treatment for haemophilia, a patient in developing countries. The standard dose is about $ 15,000 (about 12.5 lakh calls), which is expensive for the economically weaker portion. “We have tried to understand the effectiveness of a low dose in this study,” said Dr. Manisha Madkiyer, director of the ICMR Night Pur Center for Research Management and Control of Hemoglobinopathy, said, because the high dose it costs beyond many people. “He said that the cost of low doses of treatment will be less than 50 percent, which can save more than Rs 7 crore for a lifelong treatment for the average age of 50 years and a patient weighing 50 kg. -dose -recombinant FVIIII –propylaxis cost $ 6,282 (the cost of whose type of factor was $ 3,432 to $ 7.920).